Pharmaceutical Executive
Pharmaceutical Executive: February 2026
Volume: 46
Issue: 1
Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9
Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8
Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7
Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6
Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5
Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4
Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3
Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2
Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1
Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12
Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11
Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10
Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9
Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8
Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6
Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5
Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4
Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3
Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1
Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12
Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11
Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10
Pharmaceutical Executive: September 2023
Volume: 43
Issue: 9
Pharmaceutical Executive: August 2023
Volume: 43
Issue: 8
Pharmaceutical Executive: July 2023
Volume: 43
Issue: 7
Pharmaceutical Executive: June 2023
Volume: 43
Issue: 6
Pharmaceutical Executive: May 2023
Volume: 43
Issue: 5
Pharmaceutical Executive: April 2023
Volume: 43
Issue: 4
Pharmaceutical Executive: March 2023
Volume: 43
Issue: 3
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
Agentic AI and the Future of Commercial Excellence in Life Sciences
3
FDA Expands Approval for Arexvy for Adult Patients Aged 18-49
4
Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals
5